Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00531271 · ClinicalTrials.gov registry record · Phase 1
ABI-008 Trial in Patients With Metastatic Breast Cancer
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 85
- Enrollment target
NCT00531271 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 85 participants.
The verdict
NCT00531271, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 85 participants
- Enrollment target
Study Summary
To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients with metastatic breast cancer.
Interventions
- DRUG ABI-008 (nab-docetaxel)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 85 participants |
| Start Date | 2007-11-01 |
| Est. Completion | 2008-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00531271
The ClinicalTrials.gov registry entry for NCT00531271 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 85 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABI-008 (nab-docetaxel) is the first listed.
NCT00531271 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00531271 about?
NCT00531271 is a clinical study titled "ABI-008 Trial in Patients With Metastatic Breast Cancer". To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-008 giver every 3 weeks; to characterize the toxicities of ABI-008; and to determine the pharmacokinetic parameters for ABI-008 when given on an every-3-week schedule to patients with metastatic breast cancer.
What is the current status of trial NCT00531271?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 85 participants. The study started on 2007-11-01. Estimated completion is 2008-12-01.
What interventions are being tested in trial NCT00531271?
The interventions under investigation include: ABI-008 (nab-docetaxel) (DRUG).
Who is sponsoring clinical trial NCT00531271?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.